| Not Yet Recruiting | Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infecte NCT07481175 | Thomas Aagaard Rasmussen | Phase 1 |
| Recruiting | Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Expose NCT06517693 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Not Yet Recruiting | Real World Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide(BIC/FTC/TAF) in PLWH in Precarity NCT07122557 | Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba | — |
| Recruiting | Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Supp NCT06967753 | UBATEC | Phase 4 |
| Suspended | Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressi NCT06680479 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Recruiting | CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS NCT06252402 | City of Hope Medical Center | EARLY_Phase 1 |
| Recruiting | Viral Infection of HSPC Impacts Hematopoiesis NCT06458504 | Assistance Publique - Hôpitaux de Paris | — |
| Active Not Recruiting | A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral NCT05612178 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Withdrawn | MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Inf NCT05700734 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Study of CL-197 Capsules in Healthy Participants NCT05944848 | Henan Genuine Biotech Co., Ltd. | Phase 1 |
| Unknown | Third-Generation CAR-T-cell Therapy in Individuals With HIV-1 Infection NCT04863066 | Beijing 302 Hospital | Phase 1 |
| Completed | A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Comb NCT04442737 | Janssen Scientific Affairs, LLC | Phase 4 |
| Completed | A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Parti NCT04223804 | AbbVie | Phase 1 |
| Completed | Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention NCT03870438 | ANRS, Emerging Infectious Diseases | Phase 3 |
| Unknown | Preventing Childhood HIV: Rescue Intervention. ANRS 12388 PREVENIR-PEV NCT03869944 | ANRS, Emerging Infectious Diseases | Phase 2 |
| Completed | Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixe NCT04006704 | Janssen Pharmaceutica N.V., Belgium | Phase 1 |
| Terminated | A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Pho NCT03060629 | Janssen Vaccines & Prevention B.V. | Phase 2 |
| Completed | A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in NCT03227861 | Janssen Scientific Affairs, LLC | Phase 3 |
| Completed | Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact NCT02840474 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Evaluation of a Short Version Computerized Test for Processing Speed to Detect Cognitive Disorders in HIV+ Pat NCT03279835 | Centre Hospitalier Universitaire de Nice | — |
| Completed | Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, NCT02993237 | Janssen Research & Development, LLC | Phase 1 |
| Terminated | Body Composition, Bone Health and Hormonal Status in HIV-1-infected Individuals NCT03708289 | Universitair Ziekenhuis Brussel | — |
| Completed | Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, L NCT02652260 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | HIV-1, Insufficient Sleep and Vascular Endothelial Dysfunction NCT04956861 | University of Colorado, Boulder | N/A |
| Completed | A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Part NCT02217904 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue Wi NCT02547844 | Hospital Universitari Vall d'Hebron Research Institute | Phase 4 |
| Completed | HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen NCT02513147 | Hospital Universitari Vall d'Hebron Research Institute | Phase 4 |
| Completed | Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infect NCT02285114 | Gilead Sciences | Phase 2 / Phase 3 |
| Completed | Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-14 NCT02275780 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Multiple Dose BE Study With Nevirapine 400mg PR Tablets NCT02202005 | Ratiopharm GmbH | Phase 1 |
| Completed | Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Daruna NCT01968551 | Gilead Sciences | Phase 3 |
| Completed | Nutritional and Metabolic Disorders in HIV Infected Children and Adolescent NCT01771562 | ANRS, Emerging Infectious Diseases | — |
| Completed | Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Tr NCT01702090 | Janssen-Cilag Ltd. | Phase 4 |
| Completed | Korean Post-marketing Surveillance for Reyataz® NCT01450605 | Bristol-Myers Squibb | — |
| Terminated | Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral- NCT01345630 | ViiV Healthcare | Phase 3 |
| Completed | PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial NCT01192035 | University of Aarhus | Phase 4 |
| Completed | Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabi NCT01274780 | Juan A. Arnaiz | Phase 4 |
| Terminated | A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Tr NCT01254656 | Pfizer | Phase 2 |
| Completed | A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) NCT00799864 | Janssen Sciences Ireland UC | Phase 2 |
| Completed | Impact of Raltegravir on HIV-1 cDNA Slope Following Antiretroviral Therapy (ART) Initiation NCT01168167 | Christoph Stephan | — |
| Active Not Recruiting | TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants NCT00980538 | Janssen Sciences Ireland UC | Phase 3 |
| Terminated | Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART NCT01024842 | University of Oxford | Phase 1 |
| Completed | Investigation of the Safety of an HIV-1 Vaccine Given Intra-muscularly and Intra-nasally to Healthy Female Sub NCT01084343 | Mymetics Corporation | Phase 1 |
| Unknown | Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1-infected Mot NCT00981695 | Medical Research Council | Phase 1 / Phase 2 |
| Completed | Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1/2-uninfected NCT00982579 | Medical Research Council | Phase 1 |
| Completed | Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1 NCT00807443 | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Phase 2 |
| Terminated | Intrauterine Insemination In HIV-Discordant Couples NCT01173276 | Boston Medical Center | N/A |
| Unknown | Genotypic Resistant HIV Strains in Taiwan NCT00954863 | National Taiwan University Hospital | — |
| Terminated | A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1 NCT00824369 | Pfizer | Phase 2 |
| Completed | Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection NCT00850395 | ViiV Healthcare | — |
| Terminated | A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Daru NCT00823979 | Pfizer | Phase 2 |
| Unknown | A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV- NCT00840762 | Ruth M. Rothstein CORE Center | Phase 4 |
| Completed | Treatment De-Intensification and Residual HIV-1 in Youth NCT00867854 | University of North Carolina, Chapel Hill | — |
| Completed | PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Inc NCT00838760 | Tibotec Pharmaceuticals, Ireland | Phase 1 |
| Completed | A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have NCT00824421 | Pfizer | Phase 2 |
| Completed | TMC278-TiDP38-C145: A Bioavailability Study in Healthy Adult Volunteers to Evaluate 3 Pediatric Formulations o NCT00812292 | Tibotec Pharmaceuticals, Ireland | Phase 1 |
| Completed | TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infecte NCT00665847 | Tibotec Pharmaceuticals, Ireland | Phase 2 |
| Completed | ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial NCT00772902 | Gilead Sciences | Phase 4 |
| Terminated | TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC NCT00741741 | Tibotec Pharmaceuticals, Ireland | Phase 1 |
| Completed | TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in NCT00543725 | Tibotec Pharmaceuticals, Ireland | Phase 3 |
| Completed | TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combina NCT00540449 | Tibotec Pharmaceuticals, Ireland | Phase 3 |
| Completed | Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1 NCT00795444 | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Phase 2 |
| Completed | Phase 1 Safety Study of Two Experimental HIV Vaccines NCT00479999 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Dermal HIV-1 Immunization During Anti-retroviral Therapy Followed by Repeated Treatment Interruptions NCT01140139 | Swedish Institute for Infectious Disease Control | Phase 1 |
| Completed | A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodef NCT00355524 | Tibotec Pharmaceuticals, Ireland | Phase 2 |
| Completed | An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC1 NCT00359021 | Tibotec Pharmaceuticals, Ireland | Phase 3 |
| Completed | Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vac NCT00337181 | U.S. Army Medical Research and Development Command | — |
| Completed | Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada NCT00324649 | Gilead Sciences | Phase 4 |
| Completed | Fuzeon Viral Decay Pilot Study NCT00334022 | Canadian Immunodeficiency Research Collaborative | N/A |
| Completed | A Study in Asymptomatic HIV Infected Patients to Investigate Pharmacodynamics, Pharmacokinetics, Safety and To NCT00348673 | Pfizer | Phase 2 |
| Completed | Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART. NCT00298350 | Gilead Sciences | Phase 2 |
| Completed | The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Ant NCT00354627 | Tibotec Pharmaceuticals, Ireland | Phase 3 |
| Completed | A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in Belgium NCT00309205 | International Partnership for Microbicides, Inc. | Phase 1 / Phase 2 |
| Completed | A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort NCT00268827 | AIDS Arms Inc. | Phase 4 |
| Withdrawn | HLA-B35 Alleles and AIDS NCT00340223 | National Cancer Institute (NCI) | — |
| Terminated | Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjec NCT00144833 | GlaxoSmithKline | Phase 3 |
| Completed | Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received O NCT01177059 | Janssen-Cilag Pty Ltd | Phase 2 |
| Completed | Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With NCT00098293 | ViiV Healthcare | Phase 3 |
| Completed | Retrovirus Epidemiology Donor Study-II (REDS-II) NCT00097006 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adu NCT00849732 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520- NCT00849680 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | An Efficacy and Safety Study of Autologous Cluster of Differentiation 34 (CD34+) Hematopoietic Progenitor Cell NCT00074997 | Janssen-Cilag Pty Ltd | Phase 2 |
| Completed | Interventions to Decrease the Risk of Mother-to-Child Transmission of HIV in India NCT00341796 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | — |
| Completed | TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Control NCT00412646 | Tibotec Pharmaceuticals, Ireland | Phase 2 |
| Completed | Retrovirus Epidemiology Donor Study I (REDS I) NCT00005278 | National Heart, Lung, and Blood Institute (NHLBI) | — |